全球腎上腺素自動注射器市場-2022-2029
市場調查報告書
商品編碼
1140753

全球腎上腺素自動注射器市場-2022-2029

Global Epinephrine Autoinjector Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

不斷上升的過敏反應病例和對自我給藥藥物的需求不斷增長正在推動市場增長。

過敏反應是對毒物、食物或藥物的嚴重過敏反應。大多數是由蜜蜂叮咬或食用已知會引起過敏的食物引起的,例如花生和堅果。過敏反應的常見原因包括藥物、花生、堅果、昆蟲叮咬、魚、貝類和牛奶。其他可能的原因包括運動和乳膠。如果懷疑有過敏反應,應盡快將腎上腺素溶液肌肉注射到大腿外側中部,這與美國背闊肌的位置相對應。根據美國國家醫學圖書館的數據,估計有 1.6% 到 5.1% 的美國公民經歷過過敏反應。 PubMed 等臨床數據庫記錄了過敏反應發病率的上升趨勢。因此,預計過敏反應發病率的增加將推動腎上腺素的高使用率,這是一種急救選擇,推動全球市場。吸毒器的易用性和處置性也為自動注射器創造了銷售機會。這正在推動市場的增長。

但是,注射劑的多種替代方案和持續發展預計會阻礙市場增長。

地理滲透

北美將是預測期內的主要地區。

到 2021 年,北美將佔據全球腎上腺素自動注射器市場的最大市場份額。該地區已經推出了幾種腎上腺素自動注射器。也有通用產品。每個都含有藥物腎上腺素。但是每個設備都有自己的使用說明。了解差異對於獲得您想要的設備並知道如何正確使用它至關重要。患有嚴重過敏症的兒童可以在當地使用新的通用版本的 EpiPen 和 EpiPen Jr. 腎上腺素自動注射器。 2022 年 8 月,賽諾菲宣布 FDA 批准首款語音引導腎上腺素自動注射器用於危及生命的過敏患者,稱為 Auvi-Q。該公司已從 Intelliject 獲得 Auvi-Q 在北美的商業權利,而 Intelliject 保留在其他地區的商業權利。

競爭格局

全球腎上腺素自動注射器市場的主要參與者包括 ALK-Abello A/S、Amneal Pharmaceuticals Inc、Adamis Pharmaceuticals Corporation、Kaleo Inc、Mylan N.V、Novartis International AG、Pfizer Inc、Teva Pharmaceutical Industries Ltd.等。市場參與者正在努力開發具有成本效益和強大的解決方案,以獲取市場份額。主要參與者採取了多種增長戰略,例如產品發布、收購和合作夥伴關係,為全球腎上腺素自動注射器市場的增長做出了貢獻。 2022年2月,賽諾菲完成了對Amunix的收購。此次收購提供了對 Amunix 的 Pro-XTEN、XPAT 和 XPAC 技術的訪問權,以提供下一代條件激活的生物製劑。此次收購還增加了一條有前景的 T 細胞參與劑和細胞因子療法管道。 2022 年 1 月,Amneal 收購了 Saol Therapeutics 的 Baclofen 特許經營權,這是一家私營專業製藥公司。此次收購擴大了 Amneal 的神經病學商業機構和專業組合,同時在其進入生物仿製藥機構市場之前增加了商業基礎設施。

COVID-19 的影響。它對全球腎上腺素自動注射器市場產生了負面影響。

COVID-19 通過直接影響生產和需求、擾亂供應鏈、擾亂市場以及對企業和金融市場產生財務影響來影響全球經濟。大多數國家/地區都放寬了封鎖限制,但由於擔心傳播冠狀病毒(COVID-19),人們不願親自去看醫生。因此,腎上腺素自動注射器市場的公司正在擁抱遠程醫療,因為在 COVID-19 時代,個人更喜歡遠程醫療服務。在預測期內,對遠程醫療技術的需求將急劇上升。

全球腎上腺素自動注射器市場報告提供了大約 64 個市場數據表、53 個圖表和 170 頁的結構。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按劑量劃分的市場細分
  • 按年齡組劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 對患者便利性的需求不斷增加
    • 抑制因素
      • 偏好替代給藥方式
    • 市場機會
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按劑量分類

  • 0.15mg腎上腺素自動注射器
  • 0.3mg腎上腺素自動注射器
  • 0.5mg腎上腺素自動注射器

第 8 章年齡組

  • 6 歲以下
  • 6 至 12 歲
  • 12 歲以上

第 9 章最終用戶

  • 醫院
  • 診所
  • 個人

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Mylan Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • ALK-Abello AS
  • Adamis Pharmaceuticals Corp.
  • Amneal Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amedra Pharmaceuticals LLC
  • Sanofi Sa
  • Lincoln Medical Ltd
  • Antares Pharma Inc.
  • Novartis AG
  • Pfizer Inc.(Hospira Inc.)(List Not Exhaustive)

第 13 章 DataM

簡介目錄
Product Code: DMPH2877

Market Overview

Epinephrine Autoinjector Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Epinephrine (adrenaline) is a medicine used to treat conditions such as asthma, cardiac arrest, superficial bleeding, and anaphylaxis. It can also be used by inhalation for croup. Epinephrine autoinjectors are hand-held devices carried by those with severe allergies; the epinephrine delivered by the device is an emergency treatment for an anaphylactic reaction. Epinephrine autoinjector is also called EpiPen; a device used to inject a measured dose of adrenaline by autoinjector technology. The device is capable of intramuscular injection for instant and better results. The pen is designed specifically to avoid accidental punctures in the skin, as the syringe is enclosed under a protected shield and needs to operate manually to inject when kept on the patient's skin. The global Epinephrine Autoinjector Market growth is driven by several factors, such growing prevalence of allergies and their awareness among customers, increasing advancement in the product with cost-effective solutions, and rising demand for autoinjectors instead of traditional syringes.

Market Dynamics: Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex. When anaphylaxis is suspected, epinephrine solution is given as soon as possible as an intramuscular injection in the middle of the outer side of the thigh, which corresponds to the location of the vast us lateral muscle. According to the national library of medicine, between 1.6% and 5.1% of US citizens are estimated to have experienced anaphylaxis. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it is the first-aid treatment option, thereby driving the global market. Ease of usage and disposal of drug injectors has created opportunities for autoinjectors. This, in turn, is boosting the market's growth.

However, multiple alternatives for injections and continuous advancements are expected to hamper the market growth.

Market Segmentation: The 0.3mg epinephrine auto-injector segment is projected to be the dominant segment in the market during the forecast period.

Based on dosage, the market is segmented into 0.15mg epinephrine auto-injector, 0.3mg epinephrine auto-injector, and 0.5mg epinephrine auto-injector.

The 0.3mg epinephrine auto-injector accounted for the largest market share due to its various applications across all age groups and moderate doses, among others. The growth of this segment is expected to have an exponential rise during the forecast period. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. The prevalence of food allergies is high in children. Various studies have shown the majority of food allergy incidences, including anaphylaxis, occur in schools or daycare centres. Hence, epinephrine auto-injectors are considered an integral part of emergency care in schools and daycare centres.

The rising incidence of anaphylaxis in the adults & elderly is a primary factor driving the growth of the 0.5mg epinephrine auto-injector dose segment. Epinephrine is considered the first-line treatment for anaphylaxis. In addition, market players are focusing on providing generic, low-cost products. This is raising the demand for affordable treatment options for managing anaphylactic reactions.

Based on Age Group, the age group 6-12 years segment is expected to held significant market share in the fastest CAGR over the forecast period.

The age group 6-12 years children are more prone to anaphylaxis and are currently experiencing the leading position in the market and are expected to grow significantly in the forecast period. However, the prevalence of anaphylaxis is increasing in the geriatric population and is expected to grow at a considerable pace. The burden of anaphylaxis among children is growing, which requires quick and effective management. The government and regulatory bodies are giving safeguards to prevent fatal reactions among children in the 6-12 years of age group. The epinephrine, through auto-injectors, acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it has always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

Geographical Penetration: North America is the dominating region during the forecast period.

North America accounted for the largest market share of the global epinephrine autoinjector market in 2021. Several epinephrine autoinjectors are now available in the region. There are generic versions as well. Each contains the drug epinephrine. But, each device possesses its own unique set of instructions for use. Understanding the differences are essential to get the device one wants and knowing how to use it properly. Children with severe allergies now have access to a new generic version of EpiPen and EpiPen Jr. Epinephrine autoinjectors in the region. In August 2022, Sanofi Announces FDA Approval for its first voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies named, Auvi-Q. The company has licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

Competitive Landscape:

Some of the major players in the global epinephrine autoinjector market include ALK-Abello A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Epinephrine Autoinjector Market globally. In February 2022, Sanofi completed the acquisition of Amunix. This acquisition provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next-generation Conditionally Activated Biologics. Also, this acquisition adds a promising pipeline of T-cell engagers and cytokine therapies. In January 2022, Amneal acquired Saol Therapeutics' Baclofen Franchise, a private specialty pharmaceutical company. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.

COVID-19 Impact: Negative impact on the global epinephrine autoinjector market.

COVID-19 affects the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and having a financial impact on firms and financial markets. Most countries have relaxed lockdown regulations, but people are reluctant to visit doctors in person due to the fear of spreading coronavirus (COVID-19). Thus, companies in the epinephrine autoinjector market are adopting telemedicine as individuals prefer remote healthcare services during the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period.

The global epinephrine autoinjector market report would provide an access to approximately 64 market data tables, 53 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Dosage
  • 3.2. Market Snippet by Age Group
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Convenience of Patients
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Preference for Alternative Drug Delivery Modes
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Dosage

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Segment
  • 7.3. Market Attractiveness Index, By Dosage Segment
    • 7.3.1. 0.15mg Epinephrine Autoinjector*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. 0.3mg Epinephrine Autoinjector
    • 7.3.3. 0.5mg Epinephrine Autoinjector

8. By Age Group

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
  • 8.3. Market Attractiveness Index, By Age Group Segment
    • 8.3.1. Under 6 Years Patients*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. 6 to 12 Years Patients
    • 8.3.3. Over 12 Years Patients

9. By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Individuals

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Mylan Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. ALK-Abello AS
  • 12.3. Adamis Pharmaceuticals Corp.
  • 12.4. Amneal Pharmaceuticals Inc.
  • 12.5. Teva Pharmaceutical Industries Ltd.
  • 12.6. Amedra Pharmaceuticals LLC
  • 12.7. Sanofi Sa
  • 12.8. Lincoln Medical Ltd
  • 12.9. Antares Pharma Inc.
  • 12.10. Novartis AG
  • 12.11. Pfizer Inc.( Hospira Inc.) (List Not Exhaustive)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us